Targeted pill trial offers hope for tough cancers with genetic flaw
NCT ID NCT02286687
Summary
This study is testing an oral medication called talazoparib for people with advanced cancers that have spread, returned, or stopped responding to standard treatments. It is specifically for patients whose cancers have certain genetic changes in the BRCA pathway (like BRCA1, BRCA2, ATM, or PALB2 genes), excluding breast and ovarian cancers. The goal is to see if blocking a specific enzyme in cancer cells with this daily pill can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.